8-K: Aptose Biosciences Announces Positive Safety Review and Dose Escalation in Tuscany Trial for AML Treatment

Aptose Biosciences reports positive safety and efficacy data, leading to dose escalation in the Phase 1/2 Tuscany trial of tuspetinib-based triple drug therapy for newly diagnosed AML patients.

Summary

• Aptose Biosciences has announced the dosing of the first patient with 120 mg of tuspetinib (TUS) in the Phase 1/2 Tuscany trial.
• The trial is evaluating a triple drug therapy (TUS+VEN+AZA) for frontline treatment of newly diagnosed Acute Myeloid Leukemia (AML).
• The Cohort Safety Review Committee (CSRC) approved the dose escalation from 80 mg to 120 mg of TUS based on favorable safety and efficacy data from the first two cohorts.
• The first two dose cohorts (40 mg and 80 mg TUS) showed complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety profiles.
• No dose reductions were required for the standard-of-care therapy in combination with the 40 mg and 80 mg TUS doses.
• The company anticipates enrolling 18-24 patients in the TUSCANY trial by mid-late 2025.
• Updated data, including safety, CRs, MRD, and pharmacokinetic findings, will be presented at the European Hematology Association Congress (EHA 2025) in June.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with favorable safety and efficacy data, leading to dose escalation. The management's comments and the planned presentation at EHA 2025 further contribute to the positive sentiment.

Positives

• Favorable safety and efficacy data from the first two cohorts of the TUSCANY trial.
• Achievement of complete remissions (CRs) and minimal residual disease (MRD)-negativity.
• No prolonged myelosuppression or dose-limiting toxicities observed.
• CSRC approval for dose escalation to 120 mg TUS.
• The TUS+VEN+AZA triplet is being developed as a mutation-agnostic frontline therapy for AML.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• These risks include the ability to obtain capital, the inherent risks in early-stage drug development, and changing market conditions.
• Unexpected manufacturing defects could also impact the trial.

Future Outlook

Aptose is focused on developing tuspetinib-based therapies for AML, with the TUSCANY trial aiming to establish an improved frontline treatment option. The company plans to release data as it becomes available and continue enrollment in the trial.

Management Comments

• Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, stated that the data from the first two cohorts reveal promising clinical safety and antileukemic activity.
• He also mentioned that the CSRC recommended further dose escalation based on these significant findings.

Industry Context

This announcement is relevant to the field of precision oncology and hematology, particularly in the development of new treatments for AML. The TUS+VEN+AZA triplet therapy aims to address the unmet need for effective and well-tolerated frontline treatments for diverse AML populations.

Comparison to Industry Standards

• The TUS+VEN+AZA triplet is being developed as a mutation-agnostic frontline therapy, which differentiates it from some existing treatments that are more effective in specific AML subtypes.
• Companies like AbbVie (Venetoclax) and Celgene/Bristol Myers Squibb (Azacitidine) have established standard-of-care treatments for AML, and Aptose is aiming to improve upon these with the addition of tuspetinib.
• The trial's focus on patients ineligible for induction chemotherapy aligns with the industry trend of developing less toxic therapies for older or frail patients.

Stakeholder Impact

• Positive impact on shareholders due to the promising clinical trial results.
• Potential benefit for AML patients who are ineligible for induction chemotherapy.
• Opportunity for clinical investigators to participate in a leading-edge clinical trial.

Next Steps

• Continue enrollment in the 120 mg dose cohort of the TUSCANY trial.
• Present updated data at the European Hematology Association Congress (EHA 2025) in June.
• Release data as it becomes available.

Key Dates

Keywords

tuspetinib, AML, TUSCANY trial, Aptose Biosciences, oncology, hematology, clinical trial, dose escalation, complete remission, minimal residual disease, TUS+VEN+AZA, venetoclax, azacitidine